Log in to your Inderes Free account to see all free content on this page.
Newbury Pharmaceuticals
3.84 SEK +7.87%2 investors are following this company
Newbury Pharmaceuticals is a pharmaceutical company. The company develops a pipeline of in-house developed and licensed products with a focus on specialty drugs in areas such as oncology, rare diseases, and neurology. The company conducts its business within the Scandinavian market. Newbury Pharmaceuticals was founded in 2020 and has its headquarters in Lund.
Revenue
10.27M
EBIT %
-190.75 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
NEWBRY
Daily low / high price
3.58 / 4.38
SEK
Market cap
93.15M SEK
Turnover
380.59K SEK
Volume
98K
Financial calendar
General meeting
15.01.2025
Interim report
15.01.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Karl Karlsson | 41.1 % | 41.1 % |
| AB Slädens Pensionsstiftelse Nr 3 | 15.5 % | 15.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Strong Quarterly Sales Announcement from Newbury Pharmaceuticals
Newbury Pharmaceuticals Secures Approval for Varenicline in Sweden
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio